Deaths in Novartis CAR-T trial spark autoimmune risk debate
Report says deaths in Novartis’ CAR-T trial are driving debate over acceptable risk levels in autoimmune disease.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.